Author

Linda J. Popplewell

Royal Holloway University of LondonORCID 0000-0002-9417-4073Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 1 Molecular Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alberto MalerbaiD· 2 shared Ngoc Lu‐NguyeniD· 2 shared Alexis BoulinguieziD· 1 shared Casey A. MaguireiD· 1 shared DEEANN E. WALLISiD· 1 shared Erik Westin· 1 shared George Dickson· 1 shared Hui Liu· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

Alberto MalerbaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Preclinical translation of Neurofibromatosis type 1 (NF1) exon 17 skipping using targeted U7-SnRNA packaged into engineered AAV serotypes.

Marc Moore, Kimia Rayat-Sanati, Xiaoxia Zhang, Hui Liu, Zakaria Rostamitehrani, Tarah Vijayasarathy, Erik Westin, Miguel Sena‐Esteves, Casey A. Maguire, Robert A. Kesterson, Linda J. Popplewell, DEEANN E. WALLIS

This paper evaluates AAV serotypes for delivering U7-SnRNA to induce NF1 exon 17 skipping in mice, finding AAV-F is most effective in brain and AAV-B1 in sciatic nerve.

bioRxiv · Jul 2, 2026 · PreprintGenetics

Periostin exon 17 skipping enhances the efficacy of local AAV-microdystrophin administration in a fibrotic model of Duchenne muscular dystrophy

Jessica Trundle, Alexis Boulinguiez, Ngoc Lu‐Nguyen, James March, Alberto Malerba, Linda J. Popplewell

This study shows that periostin exon 17 skipping combined with AAV-microdystrophin improves muscle function and microdystrophin expression in a fibrotic DMD model.

bioRxiv · Jan 21, 2025 · PreprintPathology

Systemic antisense therapeutics inhibiting DUX4 expression improves muscle function in an FSHD mouse model

Ngoc Lu‐Nguyen, Alberto Malerba, Shan Herath, George Dickson, Linda J. Popplewell

This study shows that systemic antisense therapy targeting DUX4 improves muscle function in an FSHD mouse model by reducing DUX4 expression and associated pathology.

Human Molecular Genetics · May 11, 2021Peer-reviewedMolecular Biology